DiFusion Technologies said it secured CE Mark approval in the European Union for its CleanFuze antimicrobial spine implant line.
Georgetown, Texas-based DiFusion said the CleanFuze devices are designed to reduce surgical site infections using its antimicrobial orthobiologic polymer.
Surgical site infections are the 4th-largest cause of death in the U.S., according to a press release.
“We are extremely gratified to announce European clearance of our CleanFuze line of antimicrobial spinal implants. This material has been in development for over 5 years and attaining this milestone represents significant value for our shareholders,” co-founder & CEO Derrick Johns said in prepared remarks.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.